The Hormonal Background of Hair Loss in Non-Scarring Alopecias.
Study Design
- Study Type
- narrative review
- Intervention
- The Hormonal Background of Hair Loss in Non-Scarring Alopecias. None
- Comparator
- Placebo
- Effect Direction
- Mixed
- Risk of Bias
- Unclear
Abstract
Hair loss is a common clinical condition connected with serious psychological distress and reduced quality of life. Hormones play an essential role in the regulation of the hair growth cycle. This review focuses on the hormonal background of hair loss, including pathophysiology, underlying endocrine disorders, and possible treatment options for alopecia. In particular, the role of androgens, including dihydrotestosterone (DHT), testosterone (T), androstenedione (A4), dehydroepiandrosterone (DHEA), and its sulfate (DHEAS), has been studied in the context of androgenetic alopecia. Androgen excess may cause miniaturization of hair follicles (HFs) in the scalp. Moreover, hair loss may occur in the case of estrogen deficiency, appearing naturally during menopause. Also, thyroid hormones and thyroid dysfunctions are linked with the most common types of alopecia, including telogen effluvium (TE), alopecia areata (AA), and androgenetic alopecia. Particular emphasis is placed on the role of the hypothalamic-pituitary-adrenal axis hormones (corticotropin-releasing hormone, adrenocorticotropic hormone (ACTH), cortisol) in stress-induced alopecia. This article also briefly discusses hormonal therapies, including 5-alpha-reductase inhibitors (finasteride, dutasteride), spironolactone, bicalutamide, estrogens, and others.
Full Text
Tables
Table 2
| Medication | Mechanism of Action | Route of Administration | Dose | Indication |
|---|---|---|---|---|
| Finasteride | 5α-reductase type II inhibitor | oral | 1 mg daily | Androgenetic alopecia |
| topical | 0.25% solution | |||
| Dutasteride | 5α-reductase type I and II inhibitor | oral | 0.5 mg daily | |
| Spironolactone | AR * antagonist, | oral | 25–200 mg daily | |
| topical | 1% gel or 5% solution twice daily | |||
| Bicalutamide | AR antagonist | oral | 10–50 mg daily | |
| Cyproterone acetate | 5α-reductase inhibitor, | oral | 50 mg daily | |
| Clascoterone | AR antagonist | topical | 1% cream | |
| Pyrilutamide | AR antagonist | topical | 0.5% solution | |
| Pumpkin seed oil | Herbal 5α-reductase inhibitor | oral | 400 mg daily | |
| Estradiol | ER agonist, | oral | 1–2 mg daily | menopause, |
| Levothyroxine | Synthetic version of human thyroxine | oral | 25–200 µg daily | hypothyroidism |
References
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
Used In Evidence Reviews
Similar Papers
Journal of the American Academy of Dermatology · 1998
Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group.
Endocrine · 2017
Androgenetic alopecia: a review.
Journal of the American Academy of Dermatology · 2017
The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis.
Journal of cosmetic dermatology · 2021
Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics.
Expert opinion on pharmacotherapy · 2010
Male androgenetic alopecia.
Journal of the American Academy of Dermatology · 2006